Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Stevens-Johnson syndrome

Last updated: September 7, 2020

Summary

Stevens-Johnson syndrome (SJS) is a rare, immune-mediated, skin reaction that results in blistering of skin and extensive epidermal detachment. SJS is generally triggered by medications (e.g., certain antibiotics and antiepileptics). The patient presents 1–3 weeks after exposure to a medication with fever and other flu-like symptoms. Painful, vesiculobullous skin lesions develop and eventually denude to form extensive skin erosions, resembling large, superficial burns. The mucous membranes are also characteristically affected and the patient presents with oral ulcers, genital ulcers, and/or severe conjunctivitis. When > 30% of the skin is affected, the condition is referred to as toxic epidermal necrolysis (TEN). SJS and TEN are associated with a high mortality as a result of hypovolemic and/or septic shock. The diagnosis is primarily clinical, but skin biopsies can be used to support the diagnosis and rule out other causes of vesiculobullous lesions. The most important therapeutic measure is to discontinue the offending drug. Supportive care (e.g., fluid resuscitation, antibiotics) may be required to treat shock.

Definition

  • A rare, immune-mediated skin reaction that leads to extensive epidermal detachment and is associated with a high mortality.
  • SJS and TEN (toxic epidermal necrolysis) are the same entity but differ in terms of disease severity (based on surface area of skin involved).
    • < 10% – SJS
    • 10–30% – SJS/TEN overlap
    • > 30%Toxic epidermal necrolysis (severe SJS)

References:[1][2]

Epidemiology

  • Annual incidence: ∼ 5 cases per 1,000,000 individuals
  • Age of onset: any age
  • Sex: > (5:3)

References:[2]

Epidemiological data refers to the US, unless otherwise specified.

Etiology

References:[1][1][2]

Pathophysiology

  • The pathogenesis is not completely understood but is thought to involve a delayed hypersensitivity reaction (type IV): ↑ activity of drug-specific cytotoxic T cells → release of granulysin; (a cytolytic protein) by an unknown mechanism → damage to keratinocytes

References:[1][2]

Clinical features

The involvement of mucous membranes differentiates SJS from staphylococcal scalded skin syndrome (SSSS) in which mucous membranes are spared!

References:[1][2]

Diagnostics

SJS is primarily a clinical diagnosis (based on history of medications and infections, especially HIV) that is supported by skin tests and laboratory findings

References:[1][1][2]

Differential diagnoses

References:[1][1][1][2]

The differential diagnoses listed here are not exhaustive.

Treatment

No definitive therapy exists. Early discontinuation of the drug and adequate supportive care are associated with better outcomes!

References:[1][3]

Complications

References:[2]

We list the most important complications. The selection is not exhaustive.

Prognosis

  • Case fatality rate
    • SJS: ∼ 10%
    • SJS/TEN overlap: ∼ 30%
    • TEN: ∼ 50%
  • Factors associated with a poor prognosis
    • Old age (> 70 years)
    • Intestinal involvement
    • Pulmonary involvement
  • Recurrence: SJS and/or TEN may recur with the use of the same or closely related offending drug.

References:[1][2]

References

  1. Nirken MH, High WA, Roujeau J-C. Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis?source=search_result&search=stevens%20johnson%20syndrome&selectedTitle=1~150.Last updated: October 25, 2016. Accessed: February 19, 2017.
  2. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  3. High WA, Nirken MH, Roujeau J-C. Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae?source=see_link§ionName=SCORTEN%20score&anchor=H150140096#H150140096.Last updated: December 7, 2016. Accessed: February 19, 2017.